A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma.

Published

Journal Article

PURPOSE: Preclinical models showed TAC-101 (4-[3,5-bis(trimethylsilyl) benzamide] benzoic acid), an oral synthetic retinoid, has anti-tumor activity in hepatocellular carcinoma (HCC). A phase I/II study was performed in advanced HCC patients (pts). PATIENTS AND METHODS: Thirty-three patients were enrolled. During Phase I, pts received 40 mg daily for 14 days q3 weeks; 2 of 5 patients developed DLT so dose was reduced to 20 mg/day. Twenty-eight patients received 20 mg/day. RESULTS: No pt had a CR or PR, but 12 of 21 (57%) had SD. Two pts (9.5%) had late PR after discontinuing TAC-101. Median survival (MS) for all 28 pts treated with 20 mg/day was 12.7 months (95% CI 8.8-22.7); MS for 21 evaluable pts was 19.2 months (95% CI 10.4-27.6). CONCLUSIONS: 20 mg of TAC- was well tolerated. Significant disease stabilization (12/21 pts, 57%), 2 late PRs, and prolonged MS (19.2 months) suggest that TAC-101 provides meaningful patient benefit.

Full Text

Duke Authors

Cited Authors

  • Higginbotham, KB; Lozano, R; Brown, T; Patt, YZ; Arima, T; Abbruzzese, JL; Thomas, MB

Published Date

  • December 2008

Published In

Volume / Issue

  • 134 / 12

Start / End Page

  • 1325 - 1335

PubMed ID

  • 18504614

Pubmed Central ID

  • 18504614

Electronic International Standard Serial Number (EISSN)

  • 1432-1335

Digital Object Identifier (DOI)

  • 10.1007/s00432-008-0406-2

Language

  • eng

Conference Location

  • Germany